Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05268302 · ClinicalTrials.gov registry record · Phase 1

Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)

A Phase 1 study, sponsored by University of Maryland, Baltimore.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target

NCT05268302 is a Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05268302, a Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this research study is to test a weakened form of an experimental dengue virus challenge at different doses to test if participants develop symptoms or circulating virus in the blood (called viremia). When volunteers are exposed to dengue on purpose, it is called a "challenge" or Dengue Human Infection Model (DHIM). The research team is collecting information about the safety of the challenge and the best dose to use. The information may help us to make a dengue challenge (a DHIM) that will test vaccines to protect people from dengue.

Interventions

  • BIOLOGICAL Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose
  • BIOLOGICAL Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose - Homologous Rechallenge

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2022-02-28
Est. Completion 2024-01-04
Phase Phase 1

Sponsor

University of Maryland, Baltimore

560 total trials

What the Registry Record Tells You About NCT05268302

The ClinicalTrials.gov registry entry for NCT05268302 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose is the first listed.

NCT05268302 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05268302 about?

NCT05268302 is a clinical study titled "Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)". The purpose of this research study is to test a weakened form of an experimental dengue virus challenge at different doses to test if participants develop symptoms or circulating virus in the blood (called viremia). When volunteers are exposed to dengue on purpose, it is called a "challenge" or Deng...

What is the current status of trial NCT05268302?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-02-28. Estimated completion is 2024-01-04.

What interventions are being tested in trial NCT05268302?

The interventions under investigation include: Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose (BIOLOGICAL), Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose - Homologous Rechallenge (BIOLOGICAL).

Who is sponsoring clinical trial NCT05268302?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.